Search

Your search keyword '"Iacovelli, Roberto"' showing total 852 results
Start Over Author "Iacovelli, Roberto"
852 results on '"Iacovelli, Roberto"'

1. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Author

Maffezzoli, Michele, Santoni, Matteo, Mazzaschi, Giulia, Rodella, Sara, Lai, Eleonora, Maruzzo, Marco, Basso, Umberto, Bimbatti, Davide, Iacovelli, Roberto, Anghelone, Annunziato, Fiala, Ondřej, Rebuzzi, Sara Elena, Fornarini, Giuseppe, Lolli, Cristian, Massari, Francesco, Rosellini, Matteo, Mollica, Veronica, Nasso, Cecilia, Acunzo, Alessandro, Silini, Enrico Maria, Quaini, Federico, De Filippo, Massimo, Brunelli, Matteo, Banna, Giuseppe L., Rescigno, Pasquale, Signori, Alessio, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

2. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Author

Massari, Francesco, Santoni, Matteo, Takeshita, Hideki, Okada, Yohei, Tapia, Jose Carlos, Basso, Umberto, Maruzzo, Marco, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Gandur, Nathalia, Lam, Elaine T., Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Kemp, Robert, Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Fiala, Ondřej, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino M., Dauster, Breno, Mennitto, Alessia, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Kopp, Ray Manneh, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchhorn, Daniel, Santini, Daniele, Bamias, Aristotelis, Bisonni, Renato, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Marchetti, Andrea, Rosellini, Matteo, Sorgentoni, Giulia, Battelli, Nicola, Buti, Sebastiano, Porta, Camillo, and Bellmunt, Joaquim

Published
2024
Full Text
View/download PDF

4. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study

Author

Iacovelli, Roberto, Ciccarese, Chiara, Buti, Sebastiano, Zucali, Paolo Andrea, Fantinel, Emanuela, Bimbatti, Davide, Verzoni, Elena, Accettura, Caterina, Bonomi, Lucia, Buttigliero, Consuelo, Fornarini, Giuseppe, Pipitone, Stefania, Atzori, Francesco, Masini, Cristina, Massari, Francesco, Primi, Francesca, Strusi, Alessandro, Giudice, Giulia Claire, Perrino, Matteo, Maruzzo, Marco, Milella, Michele, Giannarelli, Diana, Brunelli, Matteo, Procopio, Giuseppe, and Tortora, Giampaolo

Published
2024
Full Text
View/download PDF

5. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Author

Choueiri, Toni K, Albiges, Laurence, Barthélémy, Philippe, Iacovelli, Roberto, Emambux, Sheik, Molina-Cerrillo, Javier, Garmezy, Benjamin, Barata, Pedro, Basu, Arnab, Bourlon, Maria T, Moon, Helen, Ratta, Raffaele, McKay, Rana R, Chehrazi-Raffle, Alexander, Hammers, Hans, Heng, Daniel Y C, Braendle, Edgar, Beckermann, Kathryn E, McGregor, Bradley A, and Motzer, Robert J

Published
2024
Full Text
View/download PDF

7. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Author

Fiala, Ondřej, Buti, Sebastiano, Takeshita, Hideki, Okada, Yohei, Massari, Francesco, Palacios, Georgia Anguera, Dionese, Michele, Scagliarini, Sarah, Büttner, Thomas, Fornarini, Giuseppe, Myint, Zin W., Galli, Luca, Souza, Vinicius Carrera, Pichler, Renate, De Giorgi, Ugo, Quiroga, María Natalia Gandur, Gilbert, Danielle, Popovic, Lazar, Grande, Enrique, Mammone, Giulia, Berardi, Rossana, Crabb, Simon J., Molina-Cerrillo, Javier, Freitas, Marcelo, Luz, Murilo, Iacovelli, Roberto, Calabrò, Fabio, Tural, Deniz, Atzori, Francesco, Küronya, Zsófia, Chiari, Rita, Campos, Saul, Caffo, Orazio, Fay, André P., Kucharz, Jakub, Zucali, Paolo Andrea, Rinck, José Augusto, Zeppellini, Annalisa, Bastos, Diogo Assed, Aurilio, Gaetano, Mota, Augusto, Trindade, Karine, Ortega, Cinzia, Sade, Juan Pablo, Rizzo, Mimma, Vau, Nuno, Giannatempo, Patrizia, Barillas, Allan, Monteiro, Fernando Sabino Marques, Dauster, Breno, Cattrini, Carlo, Nogueira, Lucas, de Carvalho Fernandes, Roni, Seront, Emmanuel, Aceituno, Luís Garcia, Grillone, Francesco, Cutuli, Hernan Javier, Fernandez, Mauricio, Bassanelli, Maria, Roviello, Giandomenico, Abahssain, Halima, Procopio, Giuseppe, Milella, Michele, Kopecky, Jindrich, Martignetti, Angelo, Messina, Carlo, Caitano, Manuel, Inman, Eva, Kanesvaran, Ravindran, Herchenhorn, Daniel, Santini, Daniele, Manneh, Ray, Bisonni, Renato, Zakopoulou, Roubini, Mosca, Alessandra, Morelli, Franco, Maluf, Fernando, Soares, Andrey, Nunes, Fernando, Pinto, Alvaro, Zgura, Anca, Incorvaia, Lorena, Ansari, Jawaher, Zabalza, Ignacio Ortego, Landmesser, Johannes, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Battelli, Nicola, Porta, Camillo, Bellmunt, Joaquim, and Santoni, Matteo

Published
2023
Full Text
View/download PDF

8. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Author

Santoni, Matteo, Myint, Zin W., Büttner, Thomas, Takeshita, Hideki, Okada, Yohei, Lam, Elaine T., Gilbert, Danielle, Küronya, Zsófia, Tural, Deniz, Pichler, Renate, Grande, Enrique, Crabb, Simon J., Kemp, Robert, Massari, Francesco, Scagliarini, Sarah, Iacovelli, Roberto, Vau, Nuno, Basso, Umberto, Maruzzo, Marco, Molina-Cerrillo, Javier, Galli, Luca, Bamias, Aristotelis, De Giorgi, Ugo, Zucali, Paolo Andrea, Rizzo, Mimma, Seront, Emmanuel, Popovic, Lazar, Caffo, Orazio, Buti, Sebastiano, Kanesvaran, Ravindran, Kopecky, Jindrich, Kucharz, Jakub, Zeppellini, Annalisa, Fiala, Ondřej, Landmesser, Johannes, Ansari, Jawaher, Giannatempo, Patrizia, Rizzo, Alessandro, Zabalza, Ignacio Ortego, Monteiro, Fernando Sabino M., Battelli, Nicola, Calabrò, Fabio, and Porta, Camillo

Published
2023
Full Text
View/download PDF

9. Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study

Author

Mollica, Veronica, Massari, Francesco, Maruzzo, Marco, Bimbatti, Davide, Claps, Melanie, Maiorano, Brigida Anna, Vitale, Maria Giuseppa, Iacovelli, Roberto, Ermacora, Paola, Roviello, Giandomenico, Calabrò, Fabio, Caffo, Orazio, Vignani, Francesca, Grillone, Francesco, Pierantoni, Francesco, Di Napoli, Marilena, Mennitto, Alessia, Marchetti, Andrea, Mattana, Alvise, Cavo, Alessia, Bassanelli, Maria, Formisano, Luigi, Prati, Veronica, Giudice, Giulia Claire, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

10. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Merler, Sara, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, and Porta, Camillo

Published
2023
Full Text
View/download PDF

12. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Author

Santoni, Matteo, Buti, Sebastiano, Myint, Zin W., Maruzzo, Marco, Iacovelli, Roberto, Pichler, Martin, Kopecky, Jindrich, Kucharz, Jakub, Rizzo, Mimma, Galli, Luca, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Kopp, Ray Manneh, Fornarini, Giuseppe, Bourlon, Maria T., Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R., Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Massari, Francesco, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Bamias, Aristotelis, Caffo, Orazio, Procopio, Giuseppe, Sunela, Kaisa, Bassanelli, Maria, Ortega, Cinzia, Grillone, Francesco, Landmesser, Johannes, Milella, Michele, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Santini, Daniele, Vau, Nuno, Morelli, Franco, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Soares, Andrey, Bisonni, Renato, Bimbatti, Davide, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Sorgentoni, Giulia, Monteiro, Fernando Sabino M., Battelli, Nicola, Bracarda, Sergio, and Porta, Camillo

Published
2024
Full Text
View/download PDF

18. Prostate Cancer: Advanced and Metastatic Disease

Author

Iacovelli, Roberto, Ratta, Raffaele, Ciccarese, Chiara, Fantinel, Emanuela, Bimbatti, Davide, Verzoni, Elena, Procopio, Giuseppe, Riva Sanseverino, Eleonora, Editor-in-Chief, Amenta, Carlo, Series Editor, Carapezza, Marco, Series Editor, Chiodi, Marcello, Series Editor, Laghi, Andrea, Series Editor, Maresca, Bruno, Series Editor, Micale, Giorgio Domenico Maria, Series Editor, Mocciaro Li Destri, Arabella, Series Editor, Öchsner, Andreas, Series Editor, Piva, Mariacristina, Series Editor, Russo, Antonio, Series Editor, Seel, Norbert M., Series Editor, Peeters, Marc, editor, Incorvaia, Lorena, editor, and Rolfo, Christian, editor

Published
2021
Full Text
View/download PDF

19. Prostate Cancer: Locoregional Disease

Author

Iacovelli, Roberto, Mosillo, Claudia, Ciccarese, Chiara, Mazzarotto, Renzo, Cerruto, Maria Angela, Riva Sanseverino, Eleonora, Editor-in-Chief, Amenta, Carlo, Series Editor, Carapezza, Marco, Series Editor, Chiodi, Marcello, Series Editor, Laghi, Andrea, Series Editor, Maresca, Bruno, Series Editor, Micale, Giorgio Domenico Maria, Series Editor, Mocciaro Li Destri, Arabella, Series Editor, Öchsner, Andreas, Series Editor, Piva, Mariacristina, Series Editor, Russo, Antonio, Series Editor, Seel, Norbert M., Series Editor, Peeters, Marc, editor, Incorvaia, Lorena, editor, and Rolfo, Christian, editor

Published
2021
Full Text
View/download PDF

20. MP53-07 EFFICACY AND SAFETY OF THE COMBINATION OF CISPLATIN PLUS NAB-PACLITAXEL AND NIVOLUMAB WITH RADIOTHERAPY AFTER MAXIMAL TUMOR RESECTION IN NON-METASTATIC MUSCLE INVASIVE BLADDER CANCER (CNN-BC TRIAL)

Author

Racioppi, Marco, primary, Bizzarri, Francesco Pio, additional, Moosavi, Seyed Koosha, additional, Scarciglia, Eros, additional, Russo, Pierluigi, additional, Palermo, Giuseppe, additional, Sparagna, Ileana, additional, Allitto, Anna Rita, additional, Ciccarese, Chiara, additional, Tagliaferri, Luca, additional, Boldrini, Luca, additional, Gambacorta, Maria Antonietta, additional, Valentini, Vincenzo, additional, Tortora, Giampaolo, additional, and Iacovelli, Roberto, additional

Published
2024
Full Text
View/download PDF

21. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

Author

Santoni, Matteo, Massari, Francesco, Grande, Enrique, Procopio, Giuseppe, Matrana, Marc R., Rizzo, Mimma, De Giorgi, Ugo, Basso, Umberto, Milella, Michele, Iacovelli, Roberto, Aurilio, Gaetano, Incorvaia, Lorena, Buti, Sebastiano, Caffo, Orazio, Fornarini, Giuseppe, Carrozza, Francesco, Mollica, Veronica, Rizzo, Alessandro, Farag, Fady, Molina-Cerrillo, Javier, and Battelli, Nicola

Published
2021
Full Text
View/download PDF

22. Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

Author

Buti, Sebastiano, Basso, Umberto, Giannarelli, Diana, De Giorgi, Ugo, Maruzzo, Marco, Iacovelli, Roberto, Galli, Luca, Porta, Camillo, Carrozza, Francesco, Procopio, Giuseppe, Fonarini, Giuseppe, Lo Re, Giovanni, Santoni, Matteo, Sabbatini, Roberto, Cusmai, Antonio, Zucali, Paolo Andrea, Aschele, Carlo, Baldini, Editta, Zafarana, Elena, Favaretto, Adolfo, Leo, Silvana, Hamzaj, Alketa, Mirabelli, Rosanna, Nole’, Franco, Zai, Silvia, Chini, Claudio, Masini, Cristina, Fatigoni, Sonia, Rocchi, Andrea, Tamburini, Emiliano, Cortellini, Alessio, and Bersanelli, Melissa

Published
2023
Full Text
View/download PDF

24. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Salfi, Alessia, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Zakopoulou, Roubini, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Zampiva, Ilaria, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Catalini, Ilaria, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, Rizzo, Mimma, and Porta, Camillo

Published
2023
Full Text
View/download PDF

25. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Author

Vitale, Maria Giuseppa, Pipitone, Stefania, Venturelli, Marta, Baldessari, Cinzia, Porta, Camillo, Iannuzzi, Federica, Basso, Umberto, Scagliarini, Sarah, Zucali, Paolo Andrea, Galli, Luca, Rossetti, Sabrina, Caserta, Claudia, Bracarda, Sergio, Iacovelli, Roberto, Masini, Cristina, Cortellini, Alessio, Di Girolamo, Stefania, Buti, Sebastiano, Fornarini, Giuseppe, Carrozza, Francesco, Santoni, Matteo, Caputo, Francesco, Giaquinta, Stefania, Balduzzi, Sara, D’Amico, Roberto, Vitale, Giovanna, Mighali, Pasquale, and Sabbatini, Roberto

Published
2020
Full Text
View/download PDF

26. Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.

Author

Strusi, Alessandro, Pinterpe, Giada, Ciccarese, Chiara, Pedone, Romina Rose, Sarcina, Michele, Sardaro, Valeria, Belletto, Rachele, Totaro, Angelo, Racioppi, Marco, Berardi, Rossana, Tortora, Giampaolo, and Iacovelli, Roberto

Subjects
PROSTATE cancer, TRANSITIONAL cell carcinoma, CONFERENCES & conventions, PATIENT safety, PROGNOSIS
Abstract

The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. 2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.

Author

Beccia, Viria, Arduini, Daniela, Iacovelli, Roberto, Scala, Alessandro, Occhipinti, Denis, Ligato, Chiara, Roca, Luigi, Russo, Pierluigi, Foschi, Nazario, Tortora, Giampaolo, and Ciccarese, Chiara

Subjects
RENAL cell carcinoma, IMMUNE checkpoint inhibitors, OVERALL survival, PROGRESSION-free survival, CONFERENCES & conventions
Abstract

In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage. On the contrary, the results from CheckMate 914 trial showed the lack of benefit of adjuvant nivolumab. In the metastatic setting, the longer-term follow-up data of the CheckMate 9ER and CheckMate 214 trials reassessed the undoubtable role of ICI-based combination in first-line treatment, with a clear survival advantage in the subgroup of patients at intermediate/poor IMDC prognosis. No OS advantage was seen in favorable IMDC risk group patients. This 2024 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized therapy for RCC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.

Author

Ciccarese, Chiara, Anghelone, Annunziato, Stefani, Alessio, Cigliola, Antonio, Strusi, Alessandro, D'Agostino, Filippo, Bria, Emilio, Iacovelli, Roberto, and Tortora, Giampaolo

Subjects
MAJOR adverse cardiovascular events, IMMUNE checkpoint inhibitors, PROTEIN-tyrosine kinase inhibitors, HYPERTENSION, ASYMPTOMATIC patients
Abstract

Combinations of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) can be responsible for major adverse cardiovascular events (MACEs). We performed a meta-analysis to assess the relative risk (RR) of MACEs and hypertension in cancer patients treated with ICI+TKI combinations. We selected prospective trials through MEDLINE/PubMed, Cochrane Library, and ASCOMeeting abstracts. We calculated combined ORs, RRs, and 95% CIs using RevMansoftware for meta-analysis (v.5.2.3). Seven studies were selected for the analysis of MACEs (3849 patients). The incidence MACEs were 0.8% with ICI+TKI combinations, compared to 0.2% in the control arms for both any- and high-grade. ICI+TKI combinations significantly increased the risk of any- (OR = 3.21; p = 0.01) and high-grade MACEs (OR = 2.72; p = 0.05). Ten studies were selected for the analysis of hypertension (5744 patients). The incidence of treatment-related hypertension of any-grade and high-grade was41.3% (vs. 20.8%) and 26.1% (vs. 12.3%) with ICI+TKI combinations, respectively. ICI+TKI combinations significantly increased the risk of treatment-related hypertension of any-grade (RR = 2.10; p = 0.001), but not of high-grade (p = 0.11). ICI+TKI combinations increase the risk of MACEs compared to controls, although the absolute incidence is eventually low. Routine cardiovascular monitoring in asymptomatic patients is therefore not recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Author

Fizazi, Karim, Kramer, Gero, Eymard, Jean-Christophe, Sternberg, Cora N, de Bono, Johann, Castellano, Daniel, Tombal, Bertrand, Wülfing, Christian, Liontos, Michael, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Oudard, Stéphane, Facchini, Gaetano, Poole, Elizabeth M, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, Bensfia, Samira, and de Wit, Ronald

Published
2020
Full Text
View/download PDF

30. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study

Author

Buti, Sebastiano, Bersanelli, Melissa, Viansone, Alessandro, Leonetti, Alessandro, Masini, Cristina, Ratta, Raffaele, Procopio, Giuseppe, Maines, Francesca, Iacovelli, Roberto, Ciccarese, Chiara, Vitale, Maria Giuseppa, De Giorgi, Ugo, Mucciarini, Claudia, Maruzzo, Marco, Prati, Giuseppe, Lattanzi, Elisabetta, Ciammella, Patrizia, Bruni, Alessio, Andreani, Stefano, and D'Abbiero, Nunziata

Published
2020
Full Text
View/download PDF

31. Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Author

Russo, Pierluigi, primary, Palermo, Giuseppe, additional, Iacovelli, Roberto, additional, Ragonese, Mauro, additional, Ciccarese, Chiara, additional, Maioriello, Giuseppe, additional, Fantasia, Fabrizio, additional, Bizzarri, Francesco Pio, additional, Marino, Filippo, additional, Moosavi, Koosha, additional, Nigro, Domenico, additional, Filomena, Giovanni Battista, additional, Gavi, Filippo, additional, Rossi, Francesco, additional, Pinto, Francesco, additional, Racioppi, Marco, additional, and Foschi, Nazario, additional

Published
2024
Full Text
View/download PDF

34. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

Author

Iacovelli, Roberto, Ciccarese, Chiara, Facchini, Gaetano, Milella, Michele, Urbano, Federica, Basso, Umberto, De Giorgi, Ugo, Sabbatini, Roberto, Santini, Daniele, Berardi, Rossana, Santoni, Matteo, Bracarda, Sergio, Massari, Francesco, Masini, Cristina, De Tursi, Michele, Ricotta, Riccardo, Buti, Sebastiano, Zustovich, Fable, Sepe, Pierangela, Rossetti, Sabrina, Maruzzo, Marco, Cortesi, Enrico, Tortora, Giampaolo, and Procopio, Giuseppe

Published
2020
Full Text
View/download PDF

36. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives

Author

Iacovelli, Roberto, Cicala, Carlo Maria, Ciccarese, Chiara, Sacco, Emilio, Racioppi, Marco, Bassi, Pierfrancesco, Tortora, Giampaolo, Iacovelli, Roberto (ORCID:0000-0002-1750-2117), Sacco, Emilio (ORCID:0000-0003-4640-8354), Racioppi, Marco (ORCID:0000-0001-9129-8479), Bassi, Pier Francesco (ORCID:0000-0002-4313-8427), Tortora, Giampaolo (ORCID:0000-0002-1378-4962), Iacovelli, Roberto, Cicala, Carlo Maria, Ciccarese, Chiara, Sacco, Emilio, Racioppi, Marco, Bassi, Pierfrancesco, Tortora, Giampaolo, Iacovelli, Roberto (ORCID:0000-0002-1750-2117), Sacco, Emilio (ORCID:0000-0003-4640-8354), Racioppi, Marco (ORCID:0000-0001-9129-8479), Bassi, Pier Francesco (ORCID:0000-0002-4313-8427), and Tortora, Giampaolo (ORCID:0000-0002-1378-4962)

Abstract

Metastatic urothelial carcinoma (mUC) is a lethal disease for which platinum-based chemotherapy represents the standard of care; however, long-term survival is achieved only in a minority of patients. Recently, along with important advances in the comprehension of the biology of this disease, the treatment paradigm of mUC has undergone a rapid expansion with the approval of several immune-checkpoint inhibitors (ICIs) and targeted agents in both first- and second-line settings. Cisplatin-based chemotherapy remains the backbone of first-therapy for mUC; nevertheless, for those patients who do not progress after the full course of first-line chemotherapy, maintenance treatment with the anti-PD-L1 avelumab showed to prolong overall survival compared observation alone. Moreover, the disappointing results of chemotherapy in pre-treated patients have led to the investigation and the subsequent approval of the anti-PD-1 pembrolizumab, which showed an unprecedented survival benefit when compared to second-line chemotherapy. Recently, target therapy with the antibody-drug conjugate (ADC) enfortumab vedotin, directed against Nectin-4, showed outstanding results in patients treated with both chemotherapy and immunotherapy. The FGFR inhibitor erdafitinib and sacituzumab govitecan, an ADC targeting Trop-2, demonstrated encouraging activity in phase II studies and are currently under investigation in randomized phase III trials. ICIs and targeted therapies also demonstrated promising results as first-line treatment of cisplatin-ineligible patients; randomized trials of ICIs alone or in combination with targeted agents are ongoing and may broaden the therapeutic armamentarium for this category of patients. In this review, we describe the current state of art for the treatment of mUC; in addition, we present the latest evidences from the most recent literature and congress presentations. Finally, we illustrate the key ongoing clinical trials, focusing on ICIs and target therapies.

Published
2023

41. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region

Author

Maruzzo, Marco, Basso, Umberto, Borsatti, Eugenio, Evangelista, Laura, Alongi, Filippo, Caffo, Orazio, Maines, Francesca, Galuppo, Sara, De Vivo, Rocco, Zustovich, Fable, Palleschi, Dario, Zivi, Andrea, Sava, Teodoro, Sorarù, Mariella, Iacovelli, Roberto, Nicodemo, Maurizio, Baier, Susanne, Fratino, Lucia, and Zagonel, Vittorina

Published
2019
Full Text
View/download PDF

43. Is Systemic Immune-Inflammation Index a Real Non-Invasive Biomarker to Predict Oncological Outcomes in Patients Eligible for Radical Cystectomy?

Author

Russo, Pierluigi, primary, Marino, Filippo, additional, Rossi, Francesco, additional, Bizzarri, Francesco, additional, Ragonese, Mauro, additional, Dibitetto, Francesco, additional, Filomena, Giovanni, additional, Marafon, Denise, additional, Ciccarese, Chiara, additional, Iacovelli, Roberto, additional, Pandolfo, Savio, additional, Aveta, Achille, additional, Cilio, Simone, additional, Napolitano, Luigi, additional, and Foschi, Nazario, additional

Published
2023
Full Text
View/download PDF

44. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations

Author

MAFFEZZOLI, Michele, primary, SANTONI, Matteo, additional, MAZZASCHI, Giulia, additional, RODELLA, Sara, additional, LAI, Eleonora, additional, MARUZZO, Marco, additional, BASSO, Umberto, additional, BIMBATTI, Davide, additional, IACOVELLI, Roberto, additional, ANGHELONE, Annunziato, additional, FIALA, Ondřej, additional, REBUZZI, Sara Elena, additional, FORNARINI, Giuseppe, additional, LOLLI, Cristian, additional, MASSARI, Francesco, additional, ROSELLINI, Matteo, additional, MOLLICA, Veronica, additional, NASSO, Cecilia, additional, ACUNZO, Alessandro, additional, SILINI, Enrico Maria, additional, QUAINI, Federico, additional, DE FILIPPO, Massimo, additional, BRUNELLI, Matteo, additional, BANNA, Giuseppe L., additional, RESCIGNO, Pasquale, additional, SIGNORI, Alessio, additional, and BUTI, Sebastiano, additional

Published
2023
Full Text
View/download PDF

46. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib

Author

Iacovelli, Roberto, Ciccarese, Chiara, Maruzzo, Marco, Atzori, Francesco, Galli, Luca, Scagliarini, Sarah, Massari, Francesco, Verzoni, Elena, Cannella, Antonella, Maratta, Maria Grazia, Caserta, Claudia, Bimbatti, Davide, Deppieri, Filippo Maria, Dessi, Mariele, Paolieri, Federico, Riccardi, Ferdinando, Bracarda, Sergio, De Giorgi, Ugo, Basso, Umberto, Tortora, Giampaolo, and Procopio, Giuseppe

Published
2022
Full Text
View/download PDF

47. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Author

Iacovelli, Roberto, De Giorgi, Ugo, Galli, Luca, Zucali, Paolo, Nolè, Franco, Sabbatini, Roberto, Fraccon, Anna Paola, Basso, Umberto, Mosca, Alessandra, Atzori, Francesco, Santini, Daniele, Facchini, Gaetano, Fornarini, Giuseppe, Pasini, Felice, Masini, Cristina, Massari, Francesco, Buti, Sebastiano, Sava, Teodoro, Sacco, Cosimo, Ricotta, Riccardo, Sperduti, Isabella, Tortora, Giampaolo, and Porta, Camillo

Published
2018
Full Text
View/download PDF

48. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

Author

Procopio, Giuseppe, Prisciandaro, Michele, Iacovelli, Roberto, Cortesi, Enrico, Fornarini, Giuseppe, Facchini, Gaetano, Cartenì, Giacomo, Sabbatini, Roberto, Del Bene, Gabriella, Galli, Luca, Caserta, Claudia, Multari, Andrea Giovanni, Bregni, Marco, Massari, Francesco, Buti, Sebastiano, De Giorgi, Ugo, Zustovich, Fable, Milella, Michele, Calabrò, Fabio, Mancini, Maria Laura, Tortora, Giampaolo, Vernieri, Claudio, Santini, Daniele, Sorarù, Mariella, Ricotta, Riccardo, Masini, Cristina, Tucci, Marcello, Fedeli, Stefano Luzi, Ortega, Cinzia, Mecozzi, Antonella, Ratta, Raffaele, Sternberg, Cora N., and Verzoni, Elena

Published
2018
Full Text
View/download PDF

50. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Author

PORTA, Camillo, primary, BAMIAS, Aristotelis, additional, ZAKOPOULOU, Roubini, additional, MYINT, Zin W., additional, CAVASIN, Nicolò, additional, IACOVELLI, Roberto, additional, PICHLER, Martin, additional, KOPECKY, Jindrich, additional, KUCHARZ, Jakub, additional, RIZZO, Mimma, additional, GALLI, Luca, additional, BÜTTNER, Thomas, additional, DE GIORGI, Ugo, additional, KANESVARAN, Ravindran, additional, FIALA, Ondřej, additional, GRANDE, Enrique, additional, ZUCALI, Paolo A., additional, KOPP, Ray M., additional, FORNARINI, Giuseppe, additional, BOURLON, Maria T., additional, SCAGLIARINI, Sarah, additional, MOLINA-CERRILLO, Javier, additional, AURILIO, Gaetano, additional, MATRANA, Marc R., additional, PICHLER, Renate, additional, CATTRINI, Carlo, additional, BÜCHLER, Tomáš, additional, MASSARI, Francesco, additional, MOLLICA, Veronica, additional, SERONT, Emmanuel, additional, CALABRÒ, Fabio, additional, PINTO, Alvaro, additional, BERARDI, Rossana, additional, ZGURA, Anca, additional, MAMMONE, Giulia, additional, ANSARI, Jawaher, additional, ATZORI, Francesco, additional, CHIARI, Rita, additional, CAFFO, Orazio, additional, PROCOPIO, Giuseppe, additional, SUNELA, Kaisa, additional, BASSANELLI, Maria, additional, ORTEGA, Cinzia, additional, GRILLONE, Francesco, additional, LANDMESSER, Johannes, additional, MERLER, Sara, additional, MESSINA, Carlo, additional, KÜRONYA, Zsófia, additional, MOSCA, Alessandra, additional, BHUVA, Dipen, additional, SANTINI, Daniele, additional, VAU, Nuno, additional, MORELLI, Franco, additional, INCORVAIA, Lorena, additional, REBUZZI, Sara E., additional, ROVIELLO, Giandomenico, additional, SOARES, Andrey, additional, ZABALZA, Ignacio O., additional, RIZZO, Alessandro, additional, BISONNI, Renato, additional, PIERANTONI, Francesco, additional, SORGENTONI, Giulia, additional, MONTEIRO, Fernando S., additional, BATTELLI, Nicola, additional, BUTI, Sebastiano, additional, and SANTONI, Matteo, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results